标题 |
Switching to a fixed-dose combined pertuzumab and trastuzumab with recombinant human hyaluronidase subcutaneous injection to treat HER2-positive breast cancer in real-world UK clinical practice
|
网址 | |
DOI |
10.1016/j.clon.2024.103671
doi
|
其它 |
期刊:Clinical Oncology 作者:Sophie E. Harding; Annabel Borley 出版日期:2024-10-01 |
求助人 | |
下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |